The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of its confirmatory study. The post Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas appeared first on MedCity News.
AI tools can work together across the payer value chain, exchanging information, collaborating and making autonomous decisions based on business rules. Here are just a few examples of how their bottom lines are benefiting. The post How Health Plans Are Adding Up Real Value From AI appeared first on MedCity News.
Shannon Sharpe was having one of those 15-minutes-of-internet-infamy moments. Social media blew up in September after the retired Denver Broncos tight end — accidentally, he later said — broadcast some of his intimate activities online. One of his sponsors took advantage of the moment: the telehealth company Ro, which sells a variety of prescription medicines…
It has become a rhetorical theme for Democrats working to hold on to the White House: Allies of former president Donald Trump, they say, want to infuse conservative ideals into how the federal government does business. That vision is outlined in the Project 2025 “Mandate for Leadership,” a 900-page blueprint produced by the conservative Heritage Foundation and other conservative organizations…
“For too many, coverage is either unavailable or insufficient.” This is the harsh reality the American Hospital Association highlighted in a recent statement to the US Senate, urging action to address growing medical debt. Despite efforts to expand insurance coverage, hospitals continue to lose billions of dollars through unpaid bills. The statement notes that hospitals…
One key aspect of many medications is that they not only help people feel better, but often these medications can help them re-enter the workforce, work more hours, work more productively, or all of the above. However, when evaluating new treatments for diseases that impact older Medicare beneficiaries (≥65 years), should we take into account…
This KFF tracker provides up to date information on U.S. pledges thus far to four multilateral health replenishments (the Pandemic Fund, WHO, Gavi, and the Global Fund) and U.S. government support to date.
The new generation of healthcare AI innovation is promising, but there are some problems that remain when it comes to AI, such as data generalization and the high cost of adopting new tools, pointed out Dr. Arash Harzand. The post AI Holds Promise, But Concerns Around Costs and Data Remain appeared first on MedCity News.
This report examines the share of doctors participating in the provider networks of Qualified Health Plans (QHPs) offered in the individual market in the federal and state Marketplaces in 2021, and how network breadth affected costs for enrollees.